Recombinant Adenovirus 5 Vaccine Shows Promise Against Castration-Resistance Prostate Cancer
Cancer Network,
Data from a phase 1 trial of a multitargeted recombinant adenovirus 5 (Ad5) vaccine platform demonstrated safety, T-cell…
Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
Overview of attention for article published in Journal for Immunotherapy of Cancer, March 2021
Altmetric Badge
About this Attention Score
-
In the top 25% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (89th percentile)
-
High Attention Score compared to outputs of the same age and source (84th percentile)
Readers on
- mendeley
- 56 Mendeley